Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Restructuring Costs (2024 - 2025)

Historic Restructuring Costs for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Q3 2025 value amounting to $8.6 million.

  • Monte Rosa Therapeutics' Restructuring Costs rose 1501.01% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year change of. This contributed to the annual value of $29.6 million for FY2024, which is 854.64% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Restructuring Costs stood at $8.6 million for Q3 2025, which was up 1501.01% from $7.8 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Restructuring Costs high stood at $8.6 million for Q3 2025, and its period low was $6.8 million during Q1 2024.